Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 19/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 19/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372980 | 1.00 | PDCD1 (0.45) | PDCD1CD274ESR1ESR2 | |
| SCHEMBL28678804 | 0.87 | ESR1 (0.42) | PDCD1CD274ESR1ESR2 | |
| SCHEMBL30550498 | 0.87 | ESR1 (0.42) | PDCD1CD274ESR1ESR2 | |
| SCHEMBL20314600 | 0.85 | ESR1 (0.43) | PDCD1CD274ESR1ESR2 | |
| SCHEMBL24421975 | 0.84 | PDCD1 (0.53) | PDCD1CD274 | |
| SCHEMBL20294076 | 0.83 | PDCD1 (0.47) | PDCD1CD274ESR1ESR2 | |
| SCHEMBL20293974 | 0.81 | PDCD1 (0.49) | PDCD1CD274 | |
| SCHEMBL30145245 | 0.81 | PDCD1 (0.49) | PDCD1CD274 | |
| SCHEMBL20294246 | 0.81 | PDCD1 (0.42) | PDCD1CD274 | |
| SCHEMBL29621538 | 0.81 | PDCD1 (0.42) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780836-B2 | Process of preparing a PD-1/PD-L1 inhibitor | INCYTE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780836-B2 | Process of preparing a PD-1/PD-L1 inhibitor | INCYTE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| CN-115884972-A | Immunomodulator, composition and application thereof | 贝达药业股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2022022600-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2022-02-03 | — | — | WO | disclosed |
| CN-113880833-A | Biphenyl polycyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-113801111-A | Biphenyl derivative inhibitor and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-12-17 | — | — | CN | disclosed |
| CN-113365995-A | Immunomodulator, composition and method thereof | 贝达药业股份有限公司 | 2021-09-07 | — | — | CN | disclosed |
| WO-2020156323-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780836-B2 | Process of preparing a PD-1/PD-L1 inhibitor | PDCD1, CD274, PDCD1LG2 | PDCD1 1/4885CD274 2/4885ESR1 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.